Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations (original) (raw)

References

  1. Ford, D. et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet. 62, 676–689 (1998).
    Article CAS Google Scholar
  2. Peto, J. et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J. Natl Cancer Inst. 91, 943–949 (1999).
    Article CAS PubMed Google Scholar
  3. hehab, N.H., Malikzay, A., Appel, M. & Halazonetis, T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 14, 278–288 (2000).
    Google Scholar
  4. Shieh, S.Y., Ahn, J., Tamai, K., Taya, Y. & Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14, 289–300 (2000).
    CAS PubMed PubMed Central Google Scholar
  5. J-S., Collins, K.M., Brown, A.L., Lee, C-H.& Chung, J.H. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404, 201–204 (2000).
  6. Wu, X., Webster, S.R. & Chen, J. Characterization of tumor-associated Chk2 mutations. J. Biol. Chem. 276, 2971–2974 (2001).
    Article CAS PubMed Google Scholar
  7. Matsuoka, S., Huang, M. & Elledge, S.J. Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282, 1893–1897 (1998).
    Article CAS PubMed Google Scholar
  8. Chaturvedi, P. et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18, 4047–4054 (1999).
    Article CAS PubMed Google Scholar
  9. Ahn, J.Y., Schwarz, J.K., Piwnica-Worms, H. & Canman, C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 60, 5934–5936 (2000).
    CAS PubMed Google Scholar
  10. Matsuoka, S. et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl Acad. Sci. USA 97, 10389–10394 (2000).
    Article CAS PubMed PubMed Central Google Scholar
  11. Bell, D.W. et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286, 2528–2531 (1999).
    Article CAS PubMed Google Scholar
  12. Sodha, N. et al. Screening hCHK2 for mutations. Science 289, 359 (2000).
  13. Lee, S.B. et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res. 61, 8062–8067 (2001).
    CAS PubMed Google Scholar
  14. Dunning, A.M. et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 10, 843–854 (1999).
    Google Scholar
  15. Vahteristo, P. et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome. Cancer Res. 61, 5718–5722 (2001).
    CAS PubMed Google Scholar
  16. Petrij-Bosch, A. et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet. 17, 341–345 (1997).
    Article CAS PubMed Google Scholar
  17. Sodha, N. et al. A robust method for detecting CHK2/RAD53 mutations in genomic DNA. Hum. Mutat. 19, 173–177 (2002).
    Article CAS PubMed Google Scholar
  18. Lange, K., Weeks, D. & Boehnke, M. Programs for pedigree analysis. MENDEL, FISHER and dGENE. Genet. Epidemiol. 5, 471–472 (1988).
    Article CAS PubMed Google Scholar
  19. Antoniou, A.C. et al. Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population based study. Genet. Epidemiol. 21, 1–18 (2001).
    Article CAS PubMed Google Scholar

Download references

Acknowledgements

We wish to thank all individuals and families, in particular the members of EUR60, who have participated in these studies and the North Cumbria Community Genetics Project for providing controls. We thank A. Hall, K. Redman, J.-W. Coebergh, A. Wagner, T. Cole, J. Mackay, F. Odefrey, K. Kroeze-Jansema, ConFab Consortium (J. Sambrook, G. Chenevix-Trench, T. Edkins, G. Mann, J.L. Hopper), S.S. Buys, I.L. Andrulis, R. Senie, M.B. Daly, D. West, E.A. Ostrander, K. Offit, A. Osario, J. Benitez, O. Sinilnikova, E. Olàh, Y.-J. Bignon, P. Ruiz, M.D. Badzioch, H.F. Vasen, P.Tonin, H.T. Lynch, D. Stoppa-Lyonnet, F.J. Couch and G. Lenoir. This research was funded by grants from the Dutch Cancer Society, Cancer Research UK, the De Kock and Nijbakker-Morra Societies and the Deutsche Krebshilfe E.V. D.F.E. is a Principal Research Fellow of Cancer Research UK. K.L.N. and B.L.W. are supported by grants from the National Cancer Institute and funds from the Abramson Family Cancer Research Institute.

Author information

Authors and Affiliations

  1. Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
    Hanne Meijers-Heijboer, Ans van den Ouweland, Anja de Snoo, Rogier Oldenburg & Monique van Veghel-Plandsoen
  2. Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Hanne Meijers-Heijboer, Jan Klijn, Marijke Wasielewski, Antoinette Hollestelle, Ellen Crepin, Fons Elstrodt & Mieke Schutte
  3. Department of Epidemiology and Biostatistics, Erasmus Medical Center, Rotterdam, The Netherlands
    Mark Houben & Cornelia van Duijn
  4. Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Carina Bartels
  5. Department of Pathology, Erasmus Medical Center, Rotterdam, The Netherlands
    Carel Meijers
  6. Cancer Research UK Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, UK
    Lesley McGuffog, Deborah Thompson & Douglas F. Easton
  7. Cancer Genetics Section, Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, SM2 5NG, Surrey, UK
    Nayanta Sodha, Sheila Seal, Rita Barfoot, Jon Mangion, Rosalind Eeles, Richard Houlston, Nazneen Rahman & Michael R. Stratton
  8. Division of Epidemiology, German Cancer Research Centre, Heidelberg, Germany
    Jenny Chang-Claude
  9. Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK
    Diana Eccles
  10. Department of Medical Genetics, St Mary's Hospital, Manchester, UK
    D Gareth Evans
  11. Medical Genetics Unit, St Georges Medical School, London, UK
    Victoria Murday
  12. Centre for Research in Women's Health, Women's College Hospital, Toronto, Canada
    Steven Narod & Catherine Phelan
  13. Sharett Institute of Oncology, Hadassah University Hospital, Jerusalem, Israel
    Tamara Peretz
  14. Epidemiology Section, Institute of Cancer Research, Haddow Laboratories, Surrey, UK
    Julian Peto
  15. London School of Hygiene and Tropical Medicine, London, UK
    Julian Peto
  16. Department of Hematology/Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Hong Xiang Zhang, Katherine L. Nathanson & Barbara L. Weber
  17. International Agency for Research on Cancer, Lyon, France
    Csilla Szabo & David Goldgar
  18. Department of Pathology/Human Genetics, University of Leiden, Leiden, The Netherlands
    Peter Devilee
  19. Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambs, UK
    P Andrew Futreal & Michael R. Stratton

Consortia

The CHEK2-Breast Cancer Consortium

Corresponding author

Correspondence toNazneen Rahman.

Ethics declarations

Competing interests

The author declare no competing financial interests.

Rights and permissions

About this article

Cite this article

The CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations.Nat Genet 31, 55–59 (2002). https://doi.org/10.1038/ng879

Download citation